Waters Corporation reported Q1 2026 revenue of $1.267 billion, surpassing guidance due to strong organic growth of 13% and contributions from its recent acquisition of Biosciences and Diagnostic Solutions. Adjusted EPS rose 20% to $2.70 despite a GAAP loss driven by acquisition-related charges. The company raised its full-year 2026 organic revenue growth guidance to 6.5%-8% and adjusted EPS guidance to $14.40-$14.60, reflecting confidence in continued momentum from new product launches and integration synergies. Waters expects sustained growth across its divisions and plans a seamless integration of acquired businesses to drive long-term success.
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging the company may have provided misleading business information to investors in its stock-based mutual funds. Investors who purchased Pu...
CoreWeave secured a $35 billion deal with Meta, making Meta one of its largest customers through 2032. Despite this significant partnership, CoreWeave's shares fell following news related to Meta's own cloud services. The drop suggests investor conce...
Baker Hughes announced a quarterly cash dividend of $0.23 per Class A common share, payable on August 17, 2026, to shareholders recorded by August 7, 2026. The company plans to fund this dividend from operational cash flow. This dividend reflects Bak...
Morpho has experienced a notable increase in whale transactions, with 68 transfers over $100K in a single day, the highest since October 2025. This surge coincides with 337 new wallet creations, the largest growth since March 2026, indicating rising ...
